Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nicholson LJ et al. - The data establish epigenetic inactivation of ASS1 as a determinant of response to platinum chemotherapy and imply that transcriptional silencing of ASS1 contributes to treatment failure and clinical relapse in ovarian cancer. The collateral sensitivity of cells lacking endogenous ASS1 to arginine depletion suggests novel therapeutic strategies for the management of relapsed ovarian cancer.

Today in Basic Science/Genetics...keeping you current

Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression
Cellular Oncology, 12/07/09

Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients
Cellular Oncology, 12/07/09

Differential apoptotic response of human cancer cells to organoselenium compounds
Cancer Chemotherapy and Pharmacology, 12/07/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address